OTIPRIO

PeakSM

ciprofloxacin

NDAOTICINJECTABLE, SUSPENSION
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Clinical Trials (5)

NCT06815536N/ARecruiting

Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae

Started Apr 2025
3,291 enrolled
Neisseria Gonorrheae Infection
NCT04678869N/AActive Not Recruiting

CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)

Started Jun 2022
313 enrolled
Acute Lymphoblastic Leukaemia - Category
NCT04636957Phase 3Unknown

A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE)

Started Nov 2020
600 enrolled
Acute Otitis Externa
NCT04147260Phase 1Completed

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

Started Nov 2019
85 enrolled
Healthy
NCT03354598Phase 3Completed

Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

Started Aug 2018
1,671 enrolled
Uncomplicated Urinary Tract Infections

Loss of Exclusivity

LOE Date
Nov 27, 2038
154 months away
Patent Expiry
Nov 27, 2038

Patent Records (5)

Patent #ExpiryTypeUse Code
9603796
Apr 21, 2029
SubstanceProduct
U-2252
11369566
Apr 21, 2029
Product
9205048
Apr 21, 2029
U-1793
9233068
Dec 11, 2029
Product
8318817
Apr 27, 2030
U-1792